[1]沙梦晗,陈素华,亢庆玲,等.低分子肝素治疗胎儿生长受限的临床疗效分析[J].医学信息,2019,32(14):61-64.[doi:10.3969/j.issn.1006-1959.2019.14.020]
　SHA Meng-han,CHEN Su-hua,Kang Qing-ling,et al.Clinical Analysis of Low Molecular Weight Heparin in the Treatment of Fetal Growth Restriction[J].Journal of Medical Information,2019,32(14):61-64.[doi:10.3969/j.issn.1006-1959.2019.14.020]
点击复制

低分子肝素治疗胎儿生长受限的临床疗效分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年14期
页码:
61-64
栏目:
论著
出版日期:
2019-07-15

文章信息/Info

Title:
Clinical Analysis of Low Molecular Weight Heparin in the Treatment of Fetal Growth Restriction
文章编号:
1006-1959（2019）14-0061-04
作者:
沙梦晗; 陈素华; 亢庆玲; 张 洋; 余 楠; 李 伟; 乌剑利; 肖 娟
华中科技大学同济医学院附属同济医院妇产科，湖北 武汉 430030
Author(s):
SHA Meng-han; CHEN Su-hua; Kang Qing-ling; ZHANG Yang; YU Nan; LI Wei; WU Jian-li; XIAO Juan
Department of Obstetrics and Gynecology,Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology,Wuhan 430030,Hubei,China
关键词:
低分子肝素; 胎儿生长受限; 胎儿生长指标
Keywords:
Key words：Low molecular weight heparin; Fetal growth restriction; Fetal growth index
分类号:
R714.5
DOI:
10.3969/j.issn.1006-1959.2019.14.020
文献标志码:
A
摘要:
目的 分析低分子肝素治疗胎儿生长受限的临床疗效。方法 选取2012年1月~2018年12月我院收治的60例胎儿生长受限（FGR）孕妇作为研究对象。根据治疗方案不同，分为对照组和实验组，各30例。对照组采用复方氨基酸及低分子右旋糖酐等治疗，实验组在对照组治疗的基础上给予低分子肝素，比较两组治疗前后孕周、胎儿生长指标、脐血流指标、羊水指标，实验组治疗前后D-D二聚体、血小板（PLT）、部分凝血活酶时间（APTT）、凝血酶原时间（PT）。结果 两组在治疗前后孕周差值比较，差异无统计学意义（P＞0.05）；两组胎儿生长指标、S/D比值、羊水指数、羊水最大前后径比较，差异无统计学意义（P＞0.05）；实验组治疗后APTT时间延长，与治疗前比较，差异有统计学意义（P＜0.05），D-D二聚体、PLT、PT与治疗前比较，差异无统计学意义（P＞0.05）。结论 低分子肝素对胎儿生长受限与传统治疗相比并没有明显优势，临床使用尚存在争议。
Abstract:
Abstract：Objective To analyze the clinical efficacy of low molecular weight heparin in the treatment of fetal growth restriction.Methods 60 pregnant women with fetal growth restriction (FGR) admitted to our hospital from January 2012 to December 2018 were selected as subjects. According to different treatment options, they were divided into control group and experimental group, 30 cases each. The control group was treated with compound amino acid and low molecular weight dextran. The experimental group was given low molecular weight heparin on the basis of the control group. The gestational weeks before and after treatment, fetal growth index, umbilical blood flow index and amniotic fluid index were compared before and after treatment. DD dimer, platelet (PLT), partial thromboplastin time (APTT), prothrombin time (PT).Results There was no significant difference in gestational age difference between the two groups before and after treatment (P>0.05),there were no significant differences in fetal growth index, S/D ratio, amniotic fluid index, and amniotic fluid maximum anteroposterior diameter between the two groups (P>0.05). The APTT time in the experimental group was prolonged. Compared with before treatment, the difference was statistically significant (P<0.05). There was no significant difference between D-D dimer, PLT and PT before treatment (P>0.05).Conclusion Low molecular weight heparin has no obvious advantages compared with traditional treatment for fetal growth restriction. The clinical use is still controversial.

参考文献/References:

[1]Audette MC,Kingdom JC.Screening for fetal growth restriction and placental insufficiency[J]. Semin Fetal Neonatal Med,2018,23(2):119-125. [2]Sharma D,Farahbakhsh N,Shastri S,et al.Intrauterine growth restriction-part 2[J].The Journal of Maternal-Fetal & Neonatal Medicine,2016,29(24):4037-4048. [3]Skeith L.Low-molecular-weight heparin for the prevention and treatment of placenta-mediated pregnancy complications:The tides have shifted[J].Thromb Res,2018(170):207-208. [4]Vayssière C,Sentilhes L,Ego A,et al.Fetal growth restriction and intra-uterine growth restriction: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians[J].Eur J Obstet Gynecol Reprod Biol,2015(193):10-18. [5]Bulletin AP.Fetal Growth Restriction[J].Obstetrics & Gynecology,2019,133(2):e97-e109. [6]Sharma D,Shastri S,Farahbakhsh N,et al.Intrauterine growthrestriction-part 1[J].J Matern Fetal Neonatal Med,2016,29(24):3977-3987. [7]刘伯宁.胎儿宫内发育迟缓的胎盘病理变化[J].中国实用妇科与产科杂志,2002,18(1):19-20. [8]Zhang S,Regnault TR,Barker PL,et al.Placental adaptations in growth restriction[J].Nutrients,2015,7(1):360-389. [9]Beune IM,Bloomfield FH,Ganzevoort W,et al.Consensus Based Definition of Growth Restriction in the Newborn[J].J Pediatr,2018(196):71-76,e1. [10]Lausman A,McCarthy FP,Walker M,et al.Screening,diagnosis,and management of intrauterine growth restriction[J].J Obstet Gynaecol Can,2012,34(1):17-28. [11]Roberge S,Nicolaides K,Demers S,et al.The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction:systematic review and meta-analysis[J].Am J Obstet Gynecol,2017,216(2):110-120.e6. [12]Groom KM,David AL.The role of aspirin,heparin,and other interventions in the prevention and treatment of fetal growth restriction[J].Am J Obstet Gynecol,2018,218(2S):S829-S840. [13]张佩玲.低分子肝素治疗胎儿生长受限的临床应用[J].中国当代医药,2014,21(7):55-59. [14]梅耀玲.低分子肝素治疗胎儿生长受限的临床效果分析[J].中外医学研究,2019,17(2):8-10. [15]王玉霞.应用低分子肝素治疗胎儿生长受限的效果观察[J].临床研究,2018,26(9):84-85. [16]邓小梅,欧璐,向冬梅,等.低分子肝素治疗胎儿生长受限的临床效果及对新生儿结局的影响[J].中国现代医生,2015,53(17):43-45. [17]Hansen AT,Sandager P,Ramsing M,et al.Tinzaparin for the treatment of foetal growth retardation:An open-labelled randomized clinical trial[J].Thromb Res,2018(170):38-44. [18]Groom KM,Mccowan LM,Mackay LK,et al.Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history:a randomized trial[J].Am J Obstet Gynecol, 2017,216(3):296.e1-296.e14. [19]Martinelli I,Ruggenenti P,Cetin I,et al.Heparin in pregnant women with previous placenta-mediated pregnancy complications:a prospective,randomized,multicenter,controlled clinical trial[J].Blood,2012,119(14):3269-3275. [20]Rey E,Garneau P,David M,et al.Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia:a pilot randomized controlled trial[J].J Thromb Haemost,2009,7(1):58-64. [21]Rodger MA,Hague WM,Kingdom J,et al.Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia(TIPPS):a multinational open-label randomised trial[J].The Lancet,2014,384(9955):1673-1683. [22]Rodger MA,Gris JC,de Vries JIP,et al.Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications:a meta-analysis of individual patient data from randomised controlled trials[J].The Lancet,2016,388(10060):2629-2641. [23]Haddad B,Winer N,Chitrit Y,et al.Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications:A Randomized Controlled Trial[J].Obstet Gynecol,2016,128(5):1053-1063. [24]Omri A,Delaloye J,Andersen H,et al.Low molecular weight heparin Novo(LHN-1)does not cross the placenta during the second trimester of pregnancy[J].Thromb Haemost,1989,61(1):55-56.

相似文献/References:

[1]钱朝庆,刘 淼,王家平,等.肾病综合征合并肾静脉血栓应用阿加曲班疗效评价[J].医学信息,2018,31(21):135.[doi:10.3969/j.issn.1006-1959.2018.21.038]
　QIAN Chao-qing,LIU Miao,WANG Jia-ping,et al.Clinical Efficacy Evaluation of Argatroban in Nephrotic Syndrome with Renal Vein Thrombosis[J].Journal of Medical Information,2018,31(14):135.[doi:10.3969/j.issn.1006-1959.2018.21.038]
[2]陈志萍.阿托伐他汀联合低分子肝素治疗短暂性脑缺血临床疗效[J].医学信息,2019,32(09):153.[doi:10.3969/j.issn.1006-1959.2019.09.051]
　CHEN Zhi-ping.Clinical Efficacy of Atorvastatin Combined with Low Molecular Weight Heparin in the Treatment of Transient Cerebral Ischemia[J].Journal of Medical Information,2019,32(14):153.[doi:10.3969/j.issn.1006-1959.2019.09.051]
[3]王晓芳.低分子肝素治疗COPD合并Ⅱ型呼吸衰竭的临床疗效[J].医学信息,2019,32(19):155.[doi:10.3969/j.issn.1006-1959.2019.19.051]
　WANG Xiao-fang.Clinical Efficacy of Low Molecular Weight Heparin in the Treatment of COPD with Type II Respiratory Failure[J].Journal of Medical Information,2019,32(14):155.[doi:10.3969/j.issn.1006-1959.2019.19.051]
[4]钟 萍.胎儿生长受限的早期诊治[J].医学信息,2019,32(23):58.[doi:10.3969/j.issn.1006-1959.2019.23.016]
　ZHONG Ping.Early Diagnosis and Treatment of Fetal Growth Restriction[J].Journal of Medical Information,2019,32(14):58.[doi:10.3969/j.issn.1006-1959.2019.23.016]
[5]龚嘉玮,朱旭日,徐 锋,等.化瘀定痛液联合低分子肝素治疗老年粗隆间骨折围手术期肿痛的效果[J].医学信息,2020,33(03):148.[doi:10.3969/j.issn.1006-1959.2020.03.048]
　GONG Jia-wei,ZHU Xu-ri,XU Feng,et al.Effect of Huayudingtong Liquid Combined with Low-molecular-weight Heparin on Perioperative Swelling and Pain in Elderly Intertrochanteric Fractures[J].Journal of Medical Information,2020,33(14):148.[doi:10.3969/j.issn.1006-1959.2020.03.048]
[6]刘廷胜.低分子肝素结合瑞舒伐他汀与醋酸泼尼松对肾病综合征患者肾功能及炎症因子的影响[J].医学信息,2020,33(08):158.[doi:10.3969/j.issn.1006-1959.2020.08.052]
　LIU Ting-sheng.Effect of Low Molecular Weight Heparin Combined with Rosuvastatin and Prednisone Acetate in the Treatment of Patients with Nephrotic Syndrome[J].Journal of Medical Information,2020,33(14):158.[doi:10.3969/j.issn.1006-1959.2020.08.052]
[7]周浩东,哈敏文.低分子肝素对晚期非小细胞肺癌化疗疗效及预后的影响[J].医学信息,2020,33(10):161.[doi:10.3969/j.issn.1006-1959.2020.10.049]
　ZHOU Hao-dong,HA Min-wen.Effects of Low Molecular Weight Heparin on the Efficacy and Prognosis of Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2020,33(14):161.[doi:10.3969/j.issn.1006-1959.2020.10.049]
[8]隋文峰,马海英.低分子肝素治疗急性肺栓塞的疗效[J].医学信息,2020,33(16):118.[doi:10.3969/j.issn.1006-1959.2020.16.036]
　SUI Wen-feng,MA Hai-ying.Efficacy of Low Molecular Weight Heparin in the Treatment of Acute Pulmonary Embolism[J].Journal of Medical Information,2020,33(14):118.[doi:10.3969/j.issn.1006-1959.2020.16.036]
[9]张 称,刘 洋.新生儿巨细胞病毒感染的诊断、治疗研究[J].医学信息,2021,34(17):58.[doi:10.3969/j.issn.1006-1959.2021.17.015]
　ZHANG Chen,LIU Yang.Study on the Diagnosis and Treatment of Neonatal Cytomegalovirus Infection[J].Journal of Medical Information,2021,34(14):58.[doi:10.3969/j.issn.1006-1959.2021.17.015]
[10]林 瑛,刘兰兰,江美娇.低分子肝素联合气压治疗预防剖宫产术后下肢深静脉血栓的临床效果[J].医学信息,2023,36(22):132.[doi:10.3969/j.issn.1006-1959.2023.22.030]
　LIN Ying,LIU Lan-lan,JIANG Mei-jiao.Clinical Effect of Low Molecular Weight Heparin Combined with Pneumatic Compression in the Prevention of Deep Venous Thrombosis After Cesarean Section[J].Journal of Medical Information,2023,36(14):132.[doi:10.3969/j.issn.1006-1959.2023.22.030]

更新日期/Last Update: 2019-07-15